Cancer Research and Treatment

Original Articles

FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation: Jinju Park, Yiseul Choi, Young San Ko, Younghoon Kim, Jung-Soo Pyo, Bo Gun Jang, Min A Kim, Jae-Seon Lee, Mee Soo Chang, Jong-Wan Park, Byung Lan Lee; Cancer Res Treat. 2018;50(1):239-254. Published online March 24, 2017; DOI: https://doi.org/10.4143/crt.2016.580

Purpose
Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells.
Materials and Methods
Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive SNU-216 cells to lapatinib. SNU-216 LR cells with FOXO1 overexpression were generated by stable transfection of a constitutively active FOXO1 mutant (FOXO1A3). HER2 and MET in SNU-216 LR cells were downregulated using RNA interference. The sensitivity of GC cells to lapatinib and/or cisplatin was determined by crystal violet assay. In addition, Western blot analysis, luciferase reporter assay and reverse transcription–polymerase chain reaction were performed.
Results
SNU-216 LR cells showed upregulations of HER2 and MET, but downregulation of FOXO1 compared to parental SNU-216 cells. FOXO1 overexpression in SNU-216 LR cells significantly suppressed resistance to lapatinib and/or cisplatin. In addition, FOXO1 negatively controlled HER2 and MET at the transcriptional level and was negatively controlled by these molecules at the post-transcriptional level. A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin.
Conclusion
FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells. These findings provide a rationale for establishing a novel treatment strategy to overcome lapatinib resistance in a subtype of GC patients.

Citations

Citations to this article as recorded by

The novel BCL-2/BCL-XL inhibitor APG-1252-mediated cleavage of GSDME enhances the antitumor efficacy of HER2-targeted therapy in HER2-positive gastric cancer
Qiu-yun Luo, Jing Yang, Tian Di, Zeng-fei Xia, Lin Zhang, Wen-tao Pan, Shan Shi, Li-qiong Yang, Jian Sun, Miao-zhen Qiu, Da-jun Yang
Acta Pharmacologica Sinica.2025; 46(4): 1082. CrossRef
FoxO1 Deficiency in Monocytic Myeloid‐Derived Suppressor Cells Exacerbates B Cell Dysfunction in Systemic Lupus Erythematosus
Liping Tan, Wei Kong, Kangxing Zhou, Shuangan Wang, Jun Liang, Yayi Hou, Huan Dou
Arthritis & Rheumatology.2025; 77(4): 423. CrossRef
The FOXO1/G6PC axis promotes gastric cancer progression and mediates 5‐fluorouracil resistance by targeting the PI3K/AKT/mTOR signaling pathway
Anna Han, Taorui Liu, Pan Du, Mengying Wang, Jiajing Liu, Liyan Chen
Molecular Carcinogenesis.2024; 63(4): 688. CrossRef
Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy
Jin-Soo Kim, Mi Young Kim, Sungyoul Hong
International Journal of Molecular Sciences.2024; 25(11): 5975. CrossRef
HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do-Youn Oh
Nature Reviews Clinical Oncology.2024; 21(9): 675. CrossRef
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Christiana Mo, Michelle Sterpi, Hyein Jeon, Fernand Bteich
Cancers.2024; 16(16): 2854. CrossRef
Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed
Journal of Immunotherapy and Precision Oncology.2023; 6(3): 150. CrossRef
Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review
Dionne Blangé, Charlotte I. Stroes, Sarah Derks, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven
Cancer Treatment Reviews.2022; 108: 102418. CrossRef
The FOXO family of transcription factors: key molecular players in gastric cancer
Ying Liu, Xiang Ao, Yi Jia, Xiaoge Li, Yu Wang, Jianxun Wang
Journal of Molecular Medicine.2022; 100(7): 997. CrossRef
VGLL1 phosphorylation and activation promotes gastric cancer malignancy via TGF-β/ERK/RSK2 signaling
Joo-Young Im, Da-Mi Kim, Hyunkyung Park, Mi-Jung Kang, Da-Yoon Kim, Kwan Young Chang, Bo-Kyung Kim, Misun Won
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2021; 1868(1): 118892. CrossRef
The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials
BumJun Kim, Dalyong Kim, JungHan Kim, HyeongSu Kim, HyunJoo Jang
Indian Journal of Cancer.2021; 58(2): 232. CrossRef
HER2-targeted therapies in gastric cancer
Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2021; 1876(1): 188549. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Diverse roles of FOXO family members in gastric cancer
Yu-Han Chen, Chun-Lan Li, Wen-Jia Chen, Jing Liu, Hua-Tao Wu
World Journal of Gastrointestinal Oncology.2021; 13(10): 1367. CrossRef
Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies
Nehad M. Ayoub, Dalia R. Ibrahim, Amer E. Alkhalifa
Medical Oncology.2021;[Epub] CrossRef
Fertility preservation in women with ovarian cancer: Finding new pathways: A case-control study
Ali Khodadadian, Yasser Varghaiyan, Emad Babakhanzadeh, Iraj Alipourfard, Saeed Haghi-Daredeh, Amin Ghobadi, Mohsen Hemmati-Dinarvand, Mehrdad Talebi, Nasrin Ghasemi
International Journal of Reproductive BioMedicine (IJRM).2021; 19(2): 157. CrossRef
Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway
Xi Wang, Bin Lu, Chunyan Dai, Yufei Fu, Ke Hao, Bing Zhao, Zhe Chen, Li Fu
Frontiers in Oncology.2020;[Epub] CrossRef
Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning
Duck Kyun Yoo, Seung Ryul Lee, Yushin Jung, Haejun Han, Hwa Kyoung Lee, Jerome Han, Soohyun Kim, Jisu Chae, Taehoon Ryu, Junho Chung
Biomolecules.2020; 10(3): 421. CrossRef
FOXO transcription factor family in cancer and metastasis
Yannasittha Jiramongkol, Eric W.-F. Lam
Cancer and Metastasis Reviews.2020; 39(3): 681. CrossRef
In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines

Hasaya Dokduang, Wassana Jamnongkarn, Bundit Promraksa, Manida Suksawat, Sureerat Padthaisong, Malinee Thanee, Jutarop Phetcharaburanin, Nisana Namwat, Sakkarn Sangkhamanon, Attapol Titapun, Narong Khuntikeo, Poramate Klanrit, Watcharin Loilome
Drug Design, Development and Therapy.2020; Volume 14: 2319. CrossRef
MiR-27a promotes EMT in ovarian cancer through active Wnt/
Li-Ya Zhang, Yuan Chen, Jue Jia, Xi Zhu, Yan He, Li-Ming Wu
Cancer Biomarkers.2019; 24(1): 31. CrossRef
Role of FoxO Proteins in Cellular Response to Antitumor Agents
Giovanni Luca Beretta, Cristina Corno, Nadia Zaffaroni, Paola Perego
Cancers.2019; 11(1): 90. CrossRef
Members of FOX family could be drug targets of cancers
Jinhua Wang, Wan Li, Ying Zhao, De Kang, Weiqi Fu, Xiangjin Zheng, Xiaocong Pang, Guanhua Du
Pharmacology & Therapeutics.2018; 181: 183. CrossRef
FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models
Cristina Corno, Simone Stucchi, Michelandrea De Cesare, Nives Carenini, Serena Stamatakos, Emilio Ciusani, Lucia Minoli, Eugenio Scanziani, Christian Argueta, Yosef Landesman, Nadia Zaffaroni, Laura Gatti, Paola Perego
Biochemical Pharmacology.2018; 147: 93. CrossRef
Nuclear division cycle 80 promotes malignant progression and predicts clinical outcome in colorectal cancer
Xuebing Yan, Linsheng Huang, Liguo Liu, Huanlong Qin, Zhenshun Song
Cancer Medicine.2018;[Epub] CrossRef
Systems analysis of key genes and pathways in the progression of hepatocellular carcinoma
Yu-Kui Shang, Fanni Li, Yi Zhang, Ze-Kun Liu, Zi-Ling Wang, Huijie Bian, Zhi-Nan Chen
Medicine.2018; 97(23): e10892. CrossRef
The Dominant Role of Forkhead Box Proteins in Cancer
Duc-Hiep Bach, Nguyen Phuoc Long, Thi-Thu-Trang Luu, Nguyen Hoang Anh, Sung Won Kwon, Sang Kook Lee
International Journal of Molecular Sciences.2018; 19(10): 3279. CrossRef
HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
Kang-Seo Park, Yong Sang Hong, Junyoung Choi, Shinkyo Yoon, Jihoon Kang, Deokhoon Kim, Kang-Pa Lee, Hyeon-Su Im, Chang Hoon Lee, Seyoung Seo, Sang-We Kim, Dae Ho Lee, Sook Ryun Park
BMB Reports.2018; 51(12): 660. CrossRef
FOXO1 reduces tumorsphere formation capacity and has crosstalk with LGR5 signaling in gastric cancer cells
Yiseul Choi, Jinju Park, Young San Ko, Younghoon Kim, Jung-Soo Pyo, Bo Gun Jang, Min A Kim, Jae-Seon Lee, Mee Soo Chang, Byung Lan Lee
Biochemical and Biophysical Research Communication.2017; 493(3): 1349. CrossRef
Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma
Jingwen Jiang, Zhongxi Huang, Xuewu Chen, Rongcheng Luo, Hongbin Cai, Hairu Wang, Hui Zhang, Tao Sun, Yunfang Zhang
DNA and Cell Biology.2017; 36(10): 813. CrossRef

12,277 View
387 Download
30 Web of Science
30 Crossref

An Alternative Triage Strategy Based on Preoperative MRI for Avoiding Trimodality Therapy in Stage IB Cervical Cancer: Jung-Yun Lee, Jina Youm, Jae Weon Kim, Kidong Kim, Hak Jae Kim, Jeong Yeon Cho, Min A Kim, Noh Hyun Park, Yong-Sang Song; Cancer Res Treat. 2016;48(1):259-265. Published online March 20, 2015; DOI: https://doi.org/10.4143/crt.2014.370

Abstract PDF PubReader ePub

Purpose
Adjuvant chemoradiation following primary surgery is frequently indicated in patients with stage IB cervical cancer. The aim of this study is to evaluate the role of a magnetic resonance imaging (MRI)-based strategy in avoiding trimodality therapy.
Materials and Methods
We retrospectively reviewed all patients with stage IB cervical cancer treated initially with primary surgery at Seoul National University Hospital. We suggest an alternative triage strategy in which the primary treatment modality is determined based on preoperative MRI findings. Using this strategy, primary surgery is only indicated when there is no evidence of parametrial involvement (PMI) and lymph node metastasis (LNM) in the MRI results; when there is evidence of either or both of these factors, primary chemoradiation is selected. Assuming that this strategy is applied to our cohort, we evaluate how the rate of trimodality therapy is affected.
Results
Of the 254 patients in our sample, 77 (30.3%) had at least one category 1 risk factor (PMI, LNM, positive resection margin) upon pathologic examination. If the MRI-based strategy had been applied to our cohort, 168 patients would have undergone primary surgery and 86 would have undergone primary chemoradiation. Only 25 patients (9.8%) would have required trimodality therapy based on an indication of at least one category 1 pathologic risk factor following radical hysterectomy.
Conclusion
The inclusion of MRI in the decision-making process for primary treatment modality could have reduced the number of patients requiring trimodality therapy based on the indication of a category 1 risk factor from 30.3% to 9.8% in our cohort.

Citations

Citations to this article as recorded by

Deep-learning-based radiomics of intratumoral and peritumoral MRI images to predict the pathological features of adjuvant radiotherapy in early-stage cervical squamous cell carcinoma
Xue-Fang Zhang, Hong-yuan Wu, Xu-Wei Liang, Jia-Luo Chen, Jianpeng Li, Shihao Zhang, Zhigang Liu
BMC Women's Health.2024;[Epub] CrossRef
Definitive Chemoradiotherapy versus Radical Hysterectomy Followed by Tailored Adjuvant Therapy in Women with Early-Stage Cervical Cancer Presenting with Pelvic Lymph Node Metastasis on Pretreatment Evaluation: A Propensity Score Matching Analysis
Jongmoo Park, Yeon-Joo Kim, Mi-Kyung Song, Joo-Hyun Nam, Sang-Yoon Park, Young-Seok Kim, Joo-Young Kim
Cancers.2021; 13(15): 3703. CrossRef
Quality of life among survivors of early-stage cervical cancer in Taiwan: an exploration of treatment modality differences
Chia-Chun Li, Ting-Chang Chang, Yun-Fang Tsai, Lynn Chen
Quality of Life Research.2017; 26(10): 2773. CrossRef
Parametrial Involvement on Magnetic ResonanceImaging Has No Effect on the Survival of Early-StageCervical Cancer Patients
Kyungmi Yang, Won Park, Seung Jae Huh, Byung Kwan Park, Chan Kyo Kim, Byoung-Gie Kim, Duk-Soo Bae, Jeong-Won Lee
International Journal of Gynecological Cancer.2017; 27(3): 507. CrossRef
Treatment strategies for stage IB cervical cancer: A cost-effectiveness analysis from Korean, Canadian and US perspectives
Jung-Yun Lee, Janice S. Kwon, David E. Cohn, Younhee Kim, Blair Smith, Tae-Jin Lee, Jae-Weon Kim
Gynecologic Oncology.2016; 140(1): 83. CrossRef

12,305 View
85 Download
4 Web of Science
5 Crossref

Safety of Fertility-Sparing Surgery in Primary Mucinous Carcinoma of the Ovary: Jung-Yun Lee, Yu Ri Jo, Tae Hun Kim, Hee Seung Kim, Min A Kim, Jae Weon Kim, Noh Hyun Park, Yong-Sang Song; Cancer Res Treat. 2015;47(2):290-305. Published online August 29, 2014; DOI: https://doi.org/10.4143/crt.2014.004

Abstract PDF PubReader ePub

Purpose
The aim of this study is to evaluate the safety of fertility-sparing surgery as the treatment for patients with primary mucinous epithelial ovarian cancer.
Materials and Methods
A retrospective study of patients with mucinous ovarian cancer between 1991 and 2010 was performed. The demographics and survival outcomes were compared between patients who underwent fertility-sparing surgery and those who underwent radical surgery.
Results
A total of 110 patients underwent primary surgery. At the time of surgery, tumors appeared to be grossly confined to the ovaries in 90 patients, and evidence of metastasis was definite in 20 patients. Of the 90 patients with tumors that appeared to be grossly confined to the ovaries at surgical exploration, 35 (38.9%) underwent fertility-sparing surgery. The Kaplan- Meier curve and the log rank test showed no difference in either recurrence-free survival (p=0.792) or disease-specific survival (p=0.706) between the two groups. Furthermore, there was no significant difference in recurrence-free survival (p=0.126) or disease-specific survival (p=0.377) between the two groups, even when the analysis was limited to women below the age of 40. In a multivariate Cox model, fertility-sparing surgery had no effect on either recurrence-free survival (recurrence hazard ratio [HR], 1.20; 95% confidence interval [CI], 0.25 to 5.71) or disease-specific survival (death HR, 0.88; 95% CI, 0.17 to 4.60).
Conclusion
Fertility-sparing surgery in primary mucinous cancer grossly confined to the ovaries may be a safe option and one not associated with an increase in recurrence or mortality.

Citations

Citations to this article as recorded by

A Complex Case: Solid Unilateral Ovarian Mucinous Carcinoma Masquerading as Leiomyosarcoma in Postmenopausal Women
Naina Kumar, Immanuel Pradeep, Mishu Mangla, Annapurna Srirambhatla
Current Womens Health Reviews.2025;[Epub] CrossRef
Prognosis of stage-I ovarian mucinous tumors according to expansile and infiltrative types
Malek Bouhani, Stéphanie Schérier, Catherine Genestie, Mojgan Devouassoux-Shisheboran, Amandine Maulard, Francois Zaccarini, Alexandra Leary, Patricia Pautier, Philippe Morice, Sébastien Gouy
International Journal of Gynecological Cancer.2025; : 101641. CrossRef
Controversies in the management of mucinous ovarian tumors
Félix Blanc-Durand, Alexandra Leary
International Journal of Gynecological Cancer.2025; 35(3): 101679. CrossRef
Safety of fertility-sparing surgery in young women with stage I endometrioid epithelial and mucinous ovarian cancer: A population-based analysis
Jing Li, Huimin Qiao, Yunyun Liu, Chunxian Huang, Aoshuang Cheng, Zhongqiu Lin, Lijuan Wang, Huaiwu Lu
European Journal of Surgical Oncology.2024; 50(1): 107276. CrossRef
Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand
Niveditha Rajadevan, Ariane Flinkier, Hugo Saunders, Yeh Chen Lee, Clare Scott, Pearly Khaw, Prue Allan, Claire Davies, John Andrews, Michelle Wilson, Janine M Lombard, Michelle Harrison, Heshani Nesfield, Anna DeFazio, Tarek Meniawy, Kylie L Gorringe
Australian and New Zealand Journal of Obstetrics and Gynaecology.2024; 64(4): 319. CrossRef
Evaluation of Outcomes of Mucinous Ovarian Cancer Treated at a Tertiary Care Cancer Hospital in Pakistan
Syed Abdul Mannan Hamdani, Musa Azhar, Abdul Wahab, Tahira Yasmeen, Neelam Siddiqui
South Asian Journal of Cancer.2023; 12(01): 081. CrossRef
Update on Prognostic and Predictive Markers in Mucinous Ovarian Cancer
Fulvio Borella, Marco Mitidieri, Stefano Cosma, Chiara Benedetto, Luca Bertero, Stefano Fucina, Isabelle Ray-Coquard, Annalisa Carapezzi, Domenico Ferraioli
Cancers.2023; 15(4): 1172. CrossRef
Safety of fertility sparing management in invasive mucinous ovarian carcinoma
Soyoun Rachel Kim, Ainhoa Madariaga, Liat Hogen, Danielle Vicus, Allan Covens, Carlos Parra-Herran, Stephanie Lheureux, Lilian T. Gien
Gynecologic Oncology.2023; 174: 129. CrossRef
Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas
Olivia Craig, Abhimanyu Nigam, Genevieve V. Dall, Kylie Gorringe
Cold Spring Harbor Perspectives in Medicine.2023; 13(9): a038190. CrossRef
Oncological and Reproductive Outcomes After Fertility-Sparing Surgery for Stage I Mucinous Ovarian Carcinoma
Wei Lin, Dongyan Cao, Xiaohua Shi, Yan You, Jiaxin Yang, Keng Shen
Frontiers in Oncology.2022;[Epub] CrossRef
Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted?
Marc D. Algera, Willemien J. van Driel, Koen K. van de Vijver, Roy F.P.M. Kruitwagen, Christianne A.R. Lok
Current Opinion in Oncology.2022; 34(5): 497. CrossRef
Primary mucinous ovarian cancer: options for surgery and chemotherapy
Katherine C Kurnit, Michael Frumovitz
International Journal of Gynecological Cancer.2022; 32(11): 1455. CrossRef
Outcomes after Fertility-sparing Surgery for Women with Ovarian Cancer: A Systematic Review of the Literature
Alexandra Bercow, Roni Nitecki, Paula C. Brady, J.Alejandro Rauh-Hain
Journal of Minimally Invasive Gynecology.2021; 28(3): 527. CrossRef
Fertility preserving surgery in carcinoma ovary: a single institution experience
T. Subramanyeshwar Rao, KVVN Raju, Vikas Gupta, R. Rajagopalan Iyer
Indian Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review
Teska Schuurman, Sanne Zilver, Sanne Samuels, Winnie Schats, Frédéric Amant, Nienke van Trommel, Christianne Lok
Cancers.2021; 13(5): 1008. CrossRef
Fertility preservation in rare ovarian tumors
Anca Chelariu-Raicu, Lauren P Cobb, David M Gershenson
International Journal of Gynecological Cancer.2021; 31(3): 432. CrossRef
Oncologic outcomes of uterine preservation for pre-menopausal patients with stage II epithelial ovarian carcinoma
Dimitrios Nasioudis, Lakeisha Mulugeta-Gordon, Erin McMinn, Maureen Byrne, Emily M Ko, Lori Cory, Ashley F Haggerty, Nawar A Latif
International Journal of Gynecological Cancer.2021; 31(3): 480. CrossRef
Fertility-Sparing Surgery for Ovarian Cancer
Geoffroy Canlorbe, Nathalie Chabbert-Buffet, Catherine Uzan
Journal of Clinical Medicine.2021; 10(18): 4235. CrossRef
Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors
M. Bartoletti, L. Musacchio, G. Giannone, V. Tuninetti, A. Bergamini, G. Scambia, D. Lorusso, G. Valabrega, G. Mangili, F. Puglisi, S. Pignata
Cancer Treatment Reviews.2021; 101: 102298. CrossRef
Options for the Treatment of Mucinous Ovarian Carcinoma
Olivia Craig, Carolina Salazar, Kylie L. Gorringe
Current Treatment Options in Oncology.2021;[Epub] CrossRef
Fertility sparing surgery vs radical surgery for epithelial ovarian cancer: a meta-analysis of overall survival and disease-free survival
Denghua Liu, Jing Cai, Aiwei Gao, Zehua Wang, Liqiong Cai
BMC Cancer.2020;[Epub] CrossRef
Fertility‐sparing treatment for early‐stage epithelial ovarian cancer: Contemporary oncologic, reproductive and endocrinologic perspectives
Rachel S. Mandelbaum, Maximilian Klar, Tsuyoshi Takiuchi, Liat Bainvoll, Shinya Matsuzaki, Richard J. Paulson, Koji Matsuo
Journal of Obstetrics and Gynaecology Research.2020; 46(8): 1263. CrossRef
Impact of uterus‐preserving surgery on Stage I primary mucinous epithelial ovarian carcinoma: A multi‐institutional study with propensity score‐weighted analysis
Masato Yoshihara, Hiroaki Kajiyama, Satoshi Tamauchi, Shohei Iyoshi, Akira Yokoi, Shiro Suzuki, Michiyasu Kawai, Tetsuro Nagasaka, Kunihiko Takahashi, Shigeyuki Matsui, Fumitaka Kikkawa
International Journal of Gynecology & Obstetrics.2020; 150(2): 177. CrossRef
Tumeurs épithéliales de l’ovaire : préservation de la fertilité. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épi
C. Uzan, B. Courbiere, N. Chabbert-Buffet
Gynécologie Obstétrique Fertilité & Sénologie .2019; 47(2): 180. CrossRef
Mucinous Ovarian Carcinoma
Dan L. Longo, Philippe Morice, Sebastien Gouy, Alexandra Leary
New England Journal of Medicine.2019; 380(13): 1256. CrossRef
Early stage mucinous ovarian cancer: A review
Erin K. Crane, Jubilee Brown
Gynecologic Oncology.2018; 149(3): 598. CrossRef
Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers
Sebastien Gouy, Marine Saidani, Amandine Maulard, Slim Bach-Hamba, Enrica Bentivegna, Alexandra Leary, Patricia Pautier, Mojgan Devouassoux-Shisheboran, Catherine Genestie, Philippe Morice
The Oncologist.2018; 23(3): 324. CrossRef
Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers
Ignacio Zapardiel, Maria Cruz, Maria D. Diestro, Antonio Requena, Juan A. Garcia-Velasco
Human Reproduction Update.2016; 22(3): 281. CrossRef
Fertility-Sparing Surgery in Epithelial Ovarian Cancer
Enrica Bentivegna, Philippe Morice, Catherine Uzan, Sebastien Gouy
Future Oncology.2016; 12(3): 389. CrossRef
Mucinous ovarian cancer: A therapeutic review
Wen Xu, Jack Rush, Kirsty Rickett, Jermaine I.G. Coward
Critical Reviews in Oncology/Hematology.2016; 102: 26. CrossRef
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer
Robert Fruscio, Lorenzo Ceppi, Silvia Corso, Francesca Galli, Tiziana Dell'Anna, Federica Dell'Orto, Daniela Giuliani, Annalisa Garbi, Stefania Chiari, Costantino Mangioni, Rodolfo Milani, Irene Floriani, Nicoletta Colombo, Cristina Maria Bonazzi
British Journal of Cancer.2016; 115(6): 641. CrossRef
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues
E. Bentivegna, S. Gouy, A. Maulard, P. Pautier, A. Leary, N. Colombo, P. Morice
Annals of Oncology.2016; 27(11): 1994. CrossRef

12,857 View
109 Download
36 Web of Science
32 Crossref

Prognostic Significance of CD24 Expression in Gastric Carcinoma: Nevine S. Darwish, Min A Kim, Mee Soo Chang, Hye Seung Lee, Byung Lan Lee, Yong Il Kim, Woo Ho Kim; Cancer Res Treat. 2004;36(5):298-302. Published online October 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.298

Abstract PDF PubReader ePub

Purpose

The human CD24 antigen is a small heavily glycosylated cell surface protein, which is expressed in hematological malignancies, as well as in a large variety of solid tumors. Its expression is now known to be related to the prognosis of several kinds of tumors. This study is designed to examine the prognostic significance of CD24 in Korean gastric cancer patients.

Materials and Methods

In the present study, we examined CD24 expression in 300 consecutive cases of gastric carcinoma by immunohistochemical staining using the tissue-array method. We also investigated the clinicopathological profiles related to CD24 expression.

Results

One hundred and three cases out of 300 (34.3%) showed the positive expression of CD24. The altered expression of CD24 was significantly associated with differentiated cancer (p=0.003), the intestinal subtype according to the Lauren classification (p<0.001), the advanced stage cancer (p=0.027), with lymphatic invasion (p=0.038) and with vascular invasion (p=0.006). The survival analysis revealed that the patients with CD24 positive expression showed significantly poorer survival than those without CD24 expression. Moreover, a combined evaluation revealed that PTEN+/CD24- cases showed the best survival compared to other groups (p=0.01).

Conclusion

Positive CD24 expression occurs in a subset of gastric carcinomas and it correlates significantly with lymphatic invasion, blood vessel invasion and poor survival.

Citations

Citations to this article as recorded by

CD24 blockade as a novel strategy for cancer treatment
Yawen Wang, Haoran Yu, Mengyuan Yu, Hui Liu, Bing Zhang, Yuanyuan Wang, Simin Zhao, Qingxin Xia
International Immunopharmacology.2023; 121: 110557. CrossRef
Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200
Sun Young Moon, Minjoo Han, Gyoungah Ryu, Seong-Ah Shin, Jun Hyuck Lee, Chang Sup Lee
International Journal of Molecular Sciences.2023; 24(20): 15072. CrossRef
Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis
Mahdieh Razmi, Roya Ghods, Somayeh Vafaei, Maryam Sahlolbei, Leili Saeednejad Zanjani, Zahra Madjd
Cancer Cell International.2021;[Epub] CrossRef
Exosomes and GPI-anchored proteins: Judicious pairs for investigating biomarkers from body fluids
Michel Vidal
Advanced Drug Delivery Reviews.2020; 161-162: 110. CrossRef
CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy
Yang-Hong Ni, Xia Zhao, Wei Wang
Current Gene Therapy.2020; 20(2): 109. CrossRef
DNA Aptamers for the Malignant Transformation Marker CD24
Joanna Fafińska, Andreas Czech, Tobias Sitz, Zoya Ignatova, Ulrich Hahn
Nucleic Acid Therapeutics.2018; 28(6): 326. CrossRef
The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer
S.M. Riajul Wahab, Farhadul Islam, Vinod Gopalan, Alfred King-yin Lam
Clinical Colorectal Cancer.2017; 16(2): 93. CrossRef
Clinicopathological and Prognostic Value of CD24 Expression in Breast Cancer: A Meta-Analysis
Gao Liu, Guo-Xing Liu, Yu Fang, Zhen-Yu Cao, Hui-Hui Du, Jie Fu, Ke Qian
The International Journal of Biological Markers.2017; 32(2): 182. CrossRef
CD24 associates with EGFR and supports EGF/EGFR signaling via RhoA in gastric cancer cells
Wenjie Deng, Luo Gu, Xiaojie Li, Jianchao Zheng, Yujie Zhang, Biao Duan, Jie Cui, Jing Dong, Jun Du
Journal of Translational Medicine.2016;[Epub] CrossRef
CD24 enrichment protects while its loss increases susceptibility of juvenile chondrocytes towards inflammation
Jieun Lee, Piera Smeriglio, Jason Dragoo, William J. Maloney, Nidhi Bhutani
Arthritis Research & Therapy.2016;[Epub] CrossRef
CD44v3+/CD24− cells possess cancer stem cell-like properties in human oral squamous cell carcinoma
KEITA TODOROKI, SACHIKO OGASAWARA, JUN AKIBA, MASAMICHI NAKAYAMA, YOSHIKI NAITO, NAOKO SEKI, JINGO KUSUKAWA, HIROHISA YANO
International Journal of Oncology.2016; 48(1): 99. CrossRef
CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation
Yao-An Shen, Chia-Yu Wang, Hui-Yen Chuang, John Jeng-Jong Hwang, Wei-Hsin Chi, Chih-Hung Shu, Ching-Yin Ho, Wing-Yin Li, Yann-Jang Chen
Oncotarget.2016; 7(36): 58351. CrossRef
CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
Mi Jeong Kwon, Jinil Han, Ji Hyun Seo, Kyoung Song, Hae Min Jeong, Jong-Sun Choi, Yu Jin Kim, Seon-Heui Lee, Yoon-La Choi, Young Kee Shin, Yves St-Pierre
PLOS ONE.2015; 10(10): e0139112. CrossRef
Expression of CD24, p21, p53, and c‐myc in alpha‐fetoprotein‐producing gastric cancer: Correlation with clinicopathologic characteristics and survival
Xiaowen Liu, Hongmei Yu, Hong Cai, Yanong Wang
Journal of Surgical Oncology.2014; 109(8): 859. CrossRef
CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
Ying-Chao Wang, Ji-Lin Wang, Xuan Kong, Tian-Tian Sun, Hao-Yan Chen, Jie Hong, Jing-Yuan Fang
Apoptosis.2014; 19(4): 643. CrossRef
CD44 but not CD24 expression is related to poor prognosis in non-cardia adenocarcinoma of the stomach
Xueyuan Cao, Donghui Cao, MeiShan Jin, Zhifang Jia, Fei Kong, Hongxi Ma, Yinping Wang, Jing Jiang
BMC Gastroenterology.2014;[Epub] CrossRef
Hypoxia‐mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion
Nobuaki Fujikuni, Hideki Yamamoto, Kazuaki Tanabe, Yutaka Naito, Naoya Sakamoto, Yuka Tanaka, Kazuyoshi Yanagihara, Naohide Oue, Wataru Yasui, Hideki Ohdan
Cancer Science.2014; 105(11): 1411. CrossRef
Clinicopathological and Prognostic Significance of CD24 Overexpression in Patients with Gastric Cancer: A Meta-Analysis
Jing-Xun Wu, Yuan-Yuan Zhao, Xuan Wu, Han-Xiang An, Yitao Ding
PLoS ONE.2014; 9(12): e114746. CrossRef
Biomarkers for predicting future metastasis of human gastrointestinal tumors
Lui Ng, Ronnie Tung Ping Poon, Roberta Pang
Cellular and Molecular Life Sciences.2013; 70(19): 3631. CrossRef
CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
Ching-Shya Yong, Chih-Ming Ou Yang, Yenn-Hwei Chou, Chao-Sheng Liao, Chung-Wei Lee, Chin-Cheng Lee
BMC Gastroenterology.2012;[Epub] CrossRef
PTEN deletion is rare but often homogeneous in gastric cancer
Sormeh Mina, Benjamin A Bohn, Ronald Simon, Antje Krohn, Matthias Reeh, Dirk Arnold, Carsten Bokemeyer, Guido Sauter, Jakob R Izbicki, Andreas Marx, Phillip R Stahl
Journal of Clinical Pathology.2012; 65(8): 693. CrossRef
Prognostic significance of loss of c-fos protein in gastric carcinoma
Seon Pil Jin, Ji Hun Kim, Min A Kim, Han-Kwang Yang, Hee Eun Lee, Hye Seung Lee, Woo Ho Kim
Pathology & Oncology Research.2007; 13(4): 284. CrossRef
Tissue Array Methods for High-throughput Clinicopathologic Research
Hye Seung Lee, Woo Ho Kim
Cancer Research and Treatment.2006; 38(1): 1. CrossRef
Loss of DNA-dependent Protein Kinase Catalytic Subunit (DNA-PKcs) Expression in Gastric Cancers
Hye Seung Lee, Han-Kwang Yang, Woo Ho Kim, Gheeyoung Choe
Cancer Research and Treatment.2005; 37(2): 98. CrossRef
Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival
Wilko Weichert, Carsten Denkert, Mick Burkhardt, Tserenchunt Gansukh, Joachim Bellach, Peter Altevogt, Manfred Dietel, Glen Kristiansen
Clinical Cancer Research.2005; 11(18): 6574. CrossRef

9,789 View
61 Download
25 Crossref

First
Prev
Page of 1
Next
Last

Search